Hematopoietic and Lymphoid System Neoplasm Withdrawn Phase 2 Trials for Cyclophosphamide (DB00531)
Indication | Status | Phase |
---|---|---|
DBCOND0132171 (Hematopoietic and Lymphoid System Neoplasm) | Withdrawn | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | Treatment |